News

The therapeutic pipeline for neovascular age-related macular degeneration (AMD) contains a host of promising investigational agents. Only time will tell how any one will shape the future of AMD management.

Though the scenic backdrop of the Pacific Northwest at this year’s meeting of the Association for Research in Vision and Ophthalmology (ARVO) may have been different from the traditional Floridian seascape, the meeting’s world-class science continues to be at the forefront.

Much has changed since the early days of vitrectomy, as exemplified in ophthalmic texts

United Kingdom’s National Institute for Health and Care Excellence (NICE) has provisionally recommended ocriplasmin (Jetrea, ThromboGenics NV) for reimbursement within the National Health Service (NHS).

What is your diagnosis?

The Cole Eye Institute will present a Retina Summit CME symposium immediately before the ARVO 2013 annual meeting.

Optos plc has received 510(k) clearance from the FDA for microperimetry as part of the OptosOCT SLO.

Gene therapy is making headway in inherited retinal diseases that were previously thought to be untreatable.